Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A subgroup analysis of the phase III RADIANT-2 study

Daniel Castellano, Emilio Bajetta, Ashok Panneerselvam, Stephen Saletan, Walter Kocha, Thomas O'Dorisio, Lowell B. Anthony, Timothy James Hobday

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Introduction. The incidence of colorectal neuroendocrine tumors(NETs) is increasing,andpatients with this disease have particularly poor prognoses. Treatment options are limited, and survival times have not improved in the past decade. Methods. A post hoc analysis of the efficacy and tolerability of everolimus plus octreotide long-acting repeatable (LAR) was conducted in patients with colorectal NETs enrolled in the phase III RAD001 in Advanced Neuroendocrine Tumors, Second Trial (RADIANT-2) study. The primary endpoint (progression- free survival [PFS]), secondary endpoints (including objective response rate), and safety were assessed. Results. Patients with colorectal NETs receiving everolimus plus octreotide LAR had a significantly longer median PFS (29.9 months; n=19) than did those receiving placebo plus octreotide LAR (6.6 months; n = 20). Everolimus plus octreotide LAR treatment also significantly reduced the risk for disease progression (hazard ratio: 0.34; 95% confidence interval: 0.13- 0.89; p=.011). Although no objective responses were observed, tumor shrinkage was more frequently noted in theeverolimusplusoctreotideLARarmthanintheplaceboplus octreotide LAR arm (67% vs. 37%, respectively). The combination of everolimus plus octreotideLARwasgenerally well tolerated by patients with colorectal NETs; rash and stomatitis were the most commonly reported adverse events. Conclusions. Everolimus plus octreotide LAR treatment had significant benefits and improved outcomes for patients with advanced colorectal NETs compared with placebo plus octreotide LAR treatment. Results of this exploratory analysis are consistent with those reported from the RADIANT-2 primary analysis. These findings support additional investigations of everolimus plus octreotide LAR in patients with colorectal NETs.

Original languageEnglish (US)
Pages (from-to)46-53
Number of pages8
JournalOncologist
Volume18
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Octreotide
Neuroendocrine Tumors
Colorectal Neoplasms
Disease-Free Survival
Placebos
Stomatitis
Everolimus
Therapeutics
Exanthema
Disease Progression
Confidence Intervals
Safety
Survival
Incidence

Keywords

  • Colorectal cancer
  • Everolimus
  • LAR
  • Neuroendocrine tumors
  • Octreotide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors : A subgroup analysis of the phase III RADIANT-2 study. / Castellano, Daniel; Bajetta, Emilio; Panneerselvam, Ashok; Saletan, Stephen; Kocha, Walter; O'Dorisio, Thomas; Anthony, Lowell B.; Hobday, Timothy James.

In: Oncologist, Vol. 18, No. 1, 2013, p. 46-53.

Research output: Contribution to journalArticle

Castellano, Daniel ; Bajetta, Emilio ; Panneerselvam, Ashok ; Saletan, Stephen ; Kocha, Walter ; O'Dorisio, Thomas ; Anthony, Lowell B. ; Hobday, Timothy James. / Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors : A subgroup analysis of the phase III RADIANT-2 study. In: Oncologist. 2013 ; Vol. 18, No. 1. pp. 46-53.
@article{d75bf5cc6b3149d5919f9869544d9e3a,
title = "Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A subgroup analysis of the phase III RADIANT-2 study",
abstract = "Introduction. The incidence of colorectal neuroendocrine tumors(NETs) is increasing,andpatients with this disease have particularly poor prognoses. Treatment options are limited, and survival times have not improved in the past decade. Methods. A post hoc analysis of the efficacy and tolerability of everolimus plus octreotide long-acting repeatable (LAR) was conducted in patients with colorectal NETs enrolled in the phase III RAD001 in Advanced Neuroendocrine Tumors, Second Trial (RADIANT-2) study. The primary endpoint (progression- free survival [PFS]), secondary endpoints (including objective response rate), and safety were assessed. Results. Patients with colorectal NETs receiving everolimus plus octreotide LAR had a significantly longer median PFS (29.9 months; n=19) than did those receiving placebo plus octreotide LAR (6.6 months; n = 20). Everolimus plus octreotide LAR treatment also significantly reduced the risk for disease progression (hazard ratio: 0.34; 95{\%} confidence interval: 0.13- 0.89; p=.011). Although no objective responses were observed, tumor shrinkage was more frequently noted in theeverolimusplusoctreotideLARarmthanintheplaceboplus octreotide LAR arm (67{\%} vs. 37{\%}, respectively). The combination of everolimus plus octreotideLARwasgenerally well tolerated by patients with colorectal NETs; rash and stomatitis were the most commonly reported adverse events. Conclusions. Everolimus plus octreotide LAR treatment had significant benefits and improved outcomes for patients with advanced colorectal NETs compared with placebo plus octreotide LAR treatment. Results of this exploratory analysis are consistent with those reported from the RADIANT-2 primary analysis. These findings support additional investigations of everolimus plus octreotide LAR in patients with colorectal NETs.",
keywords = "Colorectal cancer, Everolimus, LAR, Neuroendocrine tumors, Octreotide",
author = "Daniel Castellano and Emilio Bajetta and Ashok Panneerselvam and Stephen Saletan and Walter Kocha and Thomas O'Dorisio and Anthony, {Lowell B.} and Hobday, {Timothy James}",
year = "2013",
doi = "10.1634/theoncologist.2012-0263",
language = "English (US)",
volume = "18",
pages = "46--53",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "1",

}

TY - JOUR

T1 - Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors

T2 - A subgroup analysis of the phase III RADIANT-2 study

AU - Castellano, Daniel

AU - Bajetta, Emilio

AU - Panneerselvam, Ashok

AU - Saletan, Stephen

AU - Kocha, Walter

AU - O'Dorisio, Thomas

AU - Anthony, Lowell B.

AU - Hobday, Timothy James

PY - 2013

Y1 - 2013

N2 - Introduction. The incidence of colorectal neuroendocrine tumors(NETs) is increasing,andpatients with this disease have particularly poor prognoses. Treatment options are limited, and survival times have not improved in the past decade. Methods. A post hoc analysis of the efficacy and tolerability of everolimus plus octreotide long-acting repeatable (LAR) was conducted in patients with colorectal NETs enrolled in the phase III RAD001 in Advanced Neuroendocrine Tumors, Second Trial (RADIANT-2) study. The primary endpoint (progression- free survival [PFS]), secondary endpoints (including objective response rate), and safety were assessed. Results. Patients with colorectal NETs receiving everolimus plus octreotide LAR had a significantly longer median PFS (29.9 months; n=19) than did those receiving placebo plus octreotide LAR (6.6 months; n = 20). Everolimus plus octreotide LAR treatment also significantly reduced the risk for disease progression (hazard ratio: 0.34; 95% confidence interval: 0.13- 0.89; p=.011). Although no objective responses were observed, tumor shrinkage was more frequently noted in theeverolimusplusoctreotideLARarmthanintheplaceboplus octreotide LAR arm (67% vs. 37%, respectively). The combination of everolimus plus octreotideLARwasgenerally well tolerated by patients with colorectal NETs; rash and stomatitis were the most commonly reported adverse events. Conclusions. Everolimus plus octreotide LAR treatment had significant benefits and improved outcomes for patients with advanced colorectal NETs compared with placebo plus octreotide LAR treatment. Results of this exploratory analysis are consistent with those reported from the RADIANT-2 primary analysis. These findings support additional investigations of everolimus plus octreotide LAR in patients with colorectal NETs.

AB - Introduction. The incidence of colorectal neuroendocrine tumors(NETs) is increasing,andpatients with this disease have particularly poor prognoses. Treatment options are limited, and survival times have not improved in the past decade. Methods. A post hoc analysis of the efficacy and tolerability of everolimus plus octreotide long-acting repeatable (LAR) was conducted in patients with colorectal NETs enrolled in the phase III RAD001 in Advanced Neuroendocrine Tumors, Second Trial (RADIANT-2) study. The primary endpoint (progression- free survival [PFS]), secondary endpoints (including objective response rate), and safety were assessed. Results. Patients with colorectal NETs receiving everolimus plus octreotide LAR had a significantly longer median PFS (29.9 months; n=19) than did those receiving placebo plus octreotide LAR (6.6 months; n = 20). Everolimus plus octreotide LAR treatment also significantly reduced the risk for disease progression (hazard ratio: 0.34; 95% confidence interval: 0.13- 0.89; p=.011). Although no objective responses were observed, tumor shrinkage was more frequently noted in theeverolimusplusoctreotideLARarmthanintheplaceboplus octreotide LAR arm (67% vs. 37%, respectively). The combination of everolimus plus octreotideLARwasgenerally well tolerated by patients with colorectal NETs; rash and stomatitis were the most commonly reported adverse events. Conclusions. Everolimus plus octreotide LAR treatment had significant benefits and improved outcomes for patients with advanced colorectal NETs compared with placebo plus octreotide LAR treatment. Results of this exploratory analysis are consistent with those reported from the RADIANT-2 primary analysis. These findings support additional investigations of everolimus plus octreotide LAR in patients with colorectal NETs.

KW - Colorectal cancer

KW - Everolimus

KW - LAR

KW - Neuroendocrine tumors

KW - Octreotide

UR - http://www.scopus.com/inward/record.url?scp=84873041855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873041855&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2012-0263

DO - 10.1634/theoncologist.2012-0263

M3 - Article

C2 - 23263288

AN - SCOPUS:84873041855

VL - 18

SP - 46

EP - 53

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -